PF-03463275   Click here for help

GtoPdb Ligand ID: 9057

Synonyms: compound 10 [PMID: 19410451] | KB-79869 | PF-3463275
Compound class: Synthetic organic
Comment: PF-03463275 is an orally available, CNS-penetrant inhibitor of SLC6A9, the GlyT1 glycine transporter [1], developed for potential anti-schizophrenia activity.

This entry represents the parent molecule. Its hydrochloride salt has PubChem CID 91799199.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 41.37
Molecular weight 376.15
XLogP 2.76
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN1CC2C(C1)C2CN(C(=O)c1ncn(c1)C)Cc1ccc(c(c1)Cl)F
Isomeric SMILES CN1C[C@@H]2[C@H](C1)C2CN(C(=O)c1ncn(c1)C)Cc1ccc(c(c1)Cl)F
InChI InChI=1S/C19H22ClFN4O/c1-23-7-13-14(8-23)15(13)9-25(19(26)18-10-24(2)11-22-18)6-12-3-4-17(21)16(20)5-12/h3-5,10-11,13-15H,6-9H2,1-2H3/t13-,14+,15?
InChI Key KYLOBHXXQOZRKK-YIONKMFJSA-N
No information available.
Summary of Clinical Use Click here for help
PF-03463275 is being evaluated in a Phase 2 clinical trial to find the optimal dose for treating cognitive impairments associated with schizophrenia (NCT01911676)
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Extracellular glycine levels are regulated in part by reuptake of glycine from the synaptic cleft by GlyT1. Thus pharmacological blockade of GlyT1 has been hypothesized to increase synaptic glycine levels and thereby potentiate NMDAR transmission, through a mechanism of coagonist stimulation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01911676 Translational Neuroscience Optimization of GlyT1 Inhibitor Phase 2 Interventional Yale University